Amyotrophic Lateral Sclerosis
VIDEO: Combination therapy showed favorable safety profile in ALS
DENVER — A combination therapy of ciprofloxacin and celecoxib demonstrated a favorable safety profile for those with amyotrophic lateral sclerosis, Merit Cudkowicz, MD, MSc, said in this Healio video.
Accelerometers may be reliable tool for measuring ALS disease progression
Wearable accelerometers may be a reliable tool to track disease progression in patients with amyotrophic lateral sclerosis, researchers wrote in The Lancet.
Combination ALS therapeutic nonsuperior to placebo in phase 3 clinical trial
DENVER — A combination therapeutic for amyotrophic lateral sclerosis was nonsuperior to placebo over 48 weeks in a phase 3 clinical trial, according to a presenter at the American Academy of Neurology annual meeting.
Amylyx pulls ALS drug Relyvrio from market in US, Canada
Amylyx Pharmaceuticals Inc. announced Relyvrio, its amyotrophic lateral sclerosis therapeutic, will be removed from the market in the United States and Canada, effective immediately.
Intra-molecular compound advanced as potential disease-modifying therapy for ALS
A Cincinnati-based life sciences company announced that one of its development candidates, ASHA-624, will be advanced as a potential disease modifying therapy for amyotrophic lateral sclerosis.
Biotech firm to expand neuro therapy indications for frontotemporal dementia, Parkinson’s
A Houston-area biotech company will expand indications of its investigational and proprietary biologic combination therapy beyond amyotrophic lateral sclerosis to include frontotemporal dementia and Parkinson’s disease.
Biotech firm receives $24M to develop neurorestorative therapies
A Boston-area biotech company has received $24 million in Series A funding to develop neurorestorative and remyelinating therapies for a broad range of neurological conditions.
Positive results reported in open label extension of novel ALS therapeutic
A clinical-stage biopharmaceutical company has reported new positive data from a 12-month long-term open label extension of the CNM-Au8 treatment arm in the HEALEY ALS Platform Trial.
Partnership to advance novel ALS combination therapy
A pharmaceutical company and a biotechnology firm have announced a development and license agreement for an investigational proprietary biologic combination therapy to treat amyotrophic lateral sclerosis.
Positive topline data reported in phase 2b trial of oral, fixed-dose ALS drug
A company specializing in treatment for neurodegenerative diseases announced positive topline data from a phase 2b clinical trial of a novel, extended release oral fixed-dose therapeutic to treat amyotrophic lateral sclerosis.